FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4292682020> ?p ?o ?g. }

• W4292682020 abstract "Aims and background A number of population pharmacokinetic (PPK) models of anti-programmed cell death-1 (PD-1) monoclonal antibodies (mAbs) in multiple tumor types have been published to characterize the influencing factors of their pharmacokinetics. This review described PPK models of anti-PD-1 mAbs that investigate the magnitude and types of covariate effects in PK parameters, provide a reference for building PPK models of other anti-PD-1 mAbs, and identify areas requiring additional research to facilitate the application of PPK models. Methods A systematic search for analyses of PPK models of eleven anti-PD-1 mAbs on the market that were carried out in humans was conducted using PubMed, Embase, and the Cochrane Library. The search covered the period from the inception of the databases to April 2022. Results Currently, there are fourteen analyses on PPK models of anti-PD-1 mAbs summarized in this review, including seven models that refer to nivolumab, four referring to pembrolizumab, one referring to cemiplimab, one referring to camrelizumab, and one referred to dostarlimab. Most analyses described the pharmacokinetics of anti-PD-1 mAbs with a two-compartment model with time-varying clearance (CL) and a sigmoidal maximum effect. The estimated CL and volume of distribution in the central (V C ) ranged from 0.179 to 0.290 L/day and 2.98 to 4.46 L, respectively. The median (range) of interindividual variability (IIV) for CL and V C was 30.9% (8.7%–50.8%) and 29.0% (4.32%–40.7%), respectively. The commonly identified significant covariates were body weight (BW) on CL and V C , and albumin (ALB), tumor type, sex, and performance status (PS) on CL. Other less assessed significant covariates included lactate dehydrogenase (LDH), immunoglobulin G (IgG), ipilimumab coadministration (IPICO) on CL, and body mass index (BMI), malignant pleural mesothelioma (MESO) on V C . Conclusion This review provides detailed information about the characteristics of PPK models of anti-PD-1 mAbs, the effects of covariates on PK parameters, and the current status of the application of the models. ALB, BW, specific tumor type, sex, and PS should be considered for the future development of the PPK model of anti-PD-1 mAbs. Other potential covariates that were assessed less frequently but still have significance (e.g., LDH, IgG, and IPICO) should not be ignored. Thus, further research and thorough investigation are needed to assess new or potential covariates, which will pave the way for personalized anti-PD-1 mAbs therapy." @default.
• W4292682020 created "2022-08-23" @default.
• W4292682020 creator A5008659449 @default.
• W4292682020 creator A5021680253 @default.
• W4292682020 creator A5053337155 @default.
• W4292682020 creator A5059006948 @default.
• W4292682020 creator A5064242136 @default.
• W4292682020 creator A5073206193 @default.
• W4292682020 date "2022-08-02" @default.
• W4292682020 modified "2023-10-18" @default.
• W4292682020 title "Population pharmacokinetic models of anti-PD-1 mAbs in patients with multiple tumor types: A systematic review" @default.
• W4292682020 cites W1986246471 @default.
• W4292682020 cites W2003064100 @default.
• W4292682020 cites W2004851132 @default.
• W4292682020 cites W2047468814 @default.
• W4292682020 cites W2049320250 @default.
• W4292682020 cites W2063194385 @default.
• W4292682020 cites W2066543180 @default.
• W4292682020 cites W2066671159 @default.
• W4292682020 cites W2067933166 @default.
• W4292682020 cites W2272044596 @default.
• W4292682020 cites W2296252503 @default.
• W4292682020 cites W2554947920 @default.
• W4292682020 cites W2560367415 @default.
• W4292682020 cites W2565164803 @default.
• W4292682020 cites W2567068937 @default.
• W4292682020 cites W2587297698 @default.
• W4292682020 cites W2612703804 @default.
• W4292682020 cites W2615652585 @default.
• W4292682020 cites W2620733650 @default.
• W4292682020 cites W2728093281 @default.
• W4292682020 cites W2782220244 @default.
• W4292682020 cites W2790308866 @default.
• W4292682020 cites W2807849948 @default.
• W4292682020 cites W2890930659 @default.
• W4292682020 cites W2895957341 @default.
• W4292682020 cites W2900068522 @default.
• W4292682020 cites W2912537198 @default.
• W4292682020 cites W2914427235 @default.
• W4292682020 cites W2914696624 @default.
• W4292682020 cites W2917299215 @default.
• W4292682020 cites W2919428266 @default.
• W4292682020 cites W2945778047 @default.
• W4292682020 cites W2946271224 @default.
• W4292682020 cites W2947160942 @default.
• W4292682020 cites W2951343526 @default.
• W4292682020 cites W2962618676 @default.
• W4292682020 cites W2962917731 @default.
• W4292682020 cites W2976118620 @default.
• W4292682020 cites W2984684785 @default.
• W4292682020 cites W2987712463 @default.
• W4292682020 cites W2999177201 @default.
• W4292682020 cites W3005030826 @default.
• W4292682020 cites W3011085857 @default.
• W4292682020 cites W3016541505 @default.
• W4292682020 cites W3081635153 @default.
• W4292682020 cites W3092278410 @default.
• W4292682020 cites W3096002369 @default.
• W4292682020 cites W3119654720 @default.
• W4292682020 cites W3123681476 @default.
• W4292682020 cites W3125359479 @default.
• W4292682020 cites W3137991873 @default.
• W4292682020 cites W3139472275 @default.
• W4292682020 cites W3161390137 @default.
• W4292682020 cites W3164183868 @default.
• W4292682020 cites W3166616264 @default.
• W4292682020 cites W3179971272 @default.
• W4292682020 cites W3210068594 @default.
• W4292682020 cites W3215311665 @default.
• W4292682020 cites W4220928743 @default.
• W4292682020 doi "https://doi.org/10.3389/fimmu.2022.871372" @default.
• W4292682020 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35983041" @default.
• W4292682020 hasPublicationYear "2022" @default.
• W4292682020 type Work @default.
• W4292682020 citedByCount "0" @default.
• W4292682020 crossrefType "journal-article" @default.
• W4292682020 hasAuthorship W4292682020A5008659449 @default.
• W4292682020 hasAuthorship W4292682020A5021680253 @default.
• W4292682020 hasAuthorship W4292682020A5053337155 @default.
• W4292682020 hasAuthorship W4292682020A5059006948 @default.
• W4292682020 hasAuthorship W4292682020A5064242136 @default.
• W4292682020 hasAuthorship W4292682020A5073206193 @default.
• W4292682020 hasBestOaLocation W42926820201 @default.
• W4292682020 hasConcept C112705442 @default.
• W4292682020 hasConcept C121608353 @default.
• W4292682020 hasConcept C126322002 @default.
• W4292682020 hasConcept C143998085 @default.
• W4292682020 hasConcept C159654299 @default.
• W4292682020 hasConcept C203014093 @default.
• W4292682020 hasConcept C2777701055 @default.
• W4292682020 hasConcept C2780030458 @default.
• W4292682020 hasConcept C2780057760 @default.
• W4292682020 hasConcept C2908647359 @default.
• W4292682020 hasConcept C3020755252 @default.
• W4292682020 hasConcept C542903549 @default.
• W4292682020 hasConcept C71924100 @default.
• W4292682020 hasConcept C98274493 @default.
• W4292682020 hasConcept C99454951 @default.
• W4292682020 hasConceptScore W4292682020C112705442 @default.
• W4292682020 hasConceptScore W4292682020C121608353 @default.

• next